Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.

Gregory Y H Lip, Lars H Rasmussen, Bertil Olsson, Eva Jensen, Bengt Hamrén, Ulf Eriksson, Karin Wåhlander

Research output: Contribution to journalArticlepeer-review

Abstract

AZD0837 is a novel oral anticoagulant investigated in clinical studies for stroke prevention in patients with atrial fibrillation (AF). It is bioconverted to its active form, AR-H067637, a potent, specific and reversible thrombin inhibitor.
Original languageEnglish
Pages (from-to)1362-1373
JournalBritish Journal of Clinical Pharmacology
Volume80
Issue number6
DOIs
Publication statusPublished - 2015

Subject classification (UKÄ)

  • Pharmacology and Toxicology

Fingerprint

Dive into the research topics of 'Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.'. Together they form a unique fingerprint.

Cite this